Brought to you by 
Shire gets rights to Parion Sciences Phase II dry eye candidate
01 May 2017
Executive Summary
Parion Sciences Inc. licensed Shire PLC exclusive global rights to develop and commercialize P321 ophthalmic solution for adults with dry eye syndrome (xerophthalmia).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Shire gets rights to Parion Sciences Phase II dry eye candidate
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice